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Summary
Objective: To evaluate the potential for tumor necrosis factor alpha (TNF)-induced focal loss of cartilage in osteoarthritic (OA) knee joints.
Design: Fresh cartilage from specified regions of OA joints was immunostained for TNF-receptor (R) bearing chondrocytes. Cartilage
explants from the same regions were cultured with or without small amounts of TNF and cumulative GAG release into supernatants
measured. Concentrations of TNF, p55 and p75 soluble (s) TNF-R in supernatants from cultured OA and non-arthritic (NA) synovium were
measured by ELISA.
Results: TNF-R bearing chondrocytes were identified in OA cartilage; more specimens contained p55 TNF-R- than p75 TNF-R-bearing
chondrocytes and differences in TNF-R distribution were apparent in cartilage from different regions of the same knees. TNF at 5, 1, 0.5
and 0.25 ng/ml (but not 0.1 ng/ml) significantly increased glycosaminoglycans (GAG) release from cartilage explants in a dose-dependent
manner. Variation in susceptibility to TNF was observed in explants from different sites. TNF and p75 sTNF-R, but not p55 sTNF-R,
concentrations were significantly higher in OA, as compared with NA, supernatants. A significant correlation between TNF and p75 sTNF-R
measurements was apparent only in NA supernatants.
Conclusions: Variations in chondrocyte TNF-R expression occur in OA cartilage in vivo. TNF at concentrations produced by OA synovium
in vitro, can degrade cartilage matrix. In most OA supernatants sTNF-R concentrations were insufficient to abrogate the effects of TNF.
Thus conditions exist in some OA knees for TNF to contribute to focal loss of cartilage. © 2000 OsteoArthritis Research Society
International
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Osteoarthritis (OA), the most common cause of disability in
the elderly, is characterized by focal loss of cartilage.
However, why cartilage is lost from specific regions of the
joint in knee OA remains unclear. It is now generally
accepted that loss of cartilage matrix results from produc-
tion of aggrecanase and other enzymes by chondrocytes in
response to catabolic cytokines produced within the joint.
For example, a strong correlation exists between specific
cleavage of aggrecan core protein at the Glu373-Ala374
bond and the release of aggrecan catabolites in response
to interleukin (IL-1) and tumor necrosis factor (TNF)1 and
fragments bearing this epitope are found in synovial fluids
from OA patients.2 In addition, IL1 and TNF are present
in OA synovial fluids3 and concentrations of both cytokines
are higher in supernatants from cultured OA synovium213than those from NA individuals.4 Furthermore, OA synovial
fluids5 and OA synovium supernatants can stimulate GAG
loss from explants (Westacott, unpublished observations).
However, cartilage is lost from specific regions of OA
knees. Thus if the cartilage catabolic cytokines IL-1 and
TNF cause focal loss of cartilage then other factors must
contribute. It is known that explants from OA cartilage are
more susceptible to the effects of IL-16 and TNF7 than
similar explants from non-arthritic (NA) cartilage and that
receptors for both cytokines are enhanced on OA chondro-
cytes.8,9 However, for enhanced receptor expression to
contribute to focal loss of cartilage, receptors for such
cytokines must be focused on chondrocytes in specific
regions of the knee joint. Moreover, susceptibility to the
effects of the cytokine, as measured by GAG release
from cartilage, must also be enhanced in those regions.
Experiments designed to test these predictions revealed
regional differences in cartilage susceptibility to TNF
which were closely related to expression of the biologically
active p55 TNF receptor (R) in both OA and NA cartilage.7
Thus focal loss of cartilage will occur in the presence
of sufficient cytokine only in those regions which are
susceptible to its effects.
However, the above conclusions can be challenged on
a number of grounds. Firstly, chondrocyte TNF-R expres-
sion was evaluated on isolated chondrocytes in vitro
and the question therefore arises as to whether these
measurements reflect the situation in vivo. Secondly, the
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explant experiments7 was higher than that detected in OA
synovial fluids (0.02–1.2 ng/ml)3 or measured in superna-
tants from cultured OA synovium (0.02–5 ng/ml).4 Finally,
although TNF may be present in OA joints at concen-
trations able to stimulate cartilage matrix degradation, its
effects may be inhibited by soluble TNF-R (sTNF-R), which
are known to be present in OA synovial fluid.10 The
purpose of this work was therefore to (a) determine if
TNF-R are present on chondrocytes in vivo, and if so,
ascertain whether chondrocytes expressing TNF-R are
distributed evenly throughout the cartilage (b) determine
the effects on cartilage matrix degradation of TNF at the
concentrations likely to be present within the OA joint and
(c) to measure sTNF-R and TNF concentrations in super-
natants from cultured OA and NA synovium to determine
whether sufficient inhibitory activity to negate the effects of
TNF can be produced within the joint.Materials and methods
TISSUE PREPARATION
Full depth slices of cartilage were removed less than 2
hours post-operatively from six specific weight-bearing and
non-weightbearing areas on the femoral condyles (Fig. 1)
of patients who fulfilled the ACR criteria for OA undergoing
surgery for total joint replacement. Details of joint damage
were recorded diagrammatically. Synovium was obtained
from the same OA joints. NA cartilage, and synovium when
available, was obtained from patients undergoing hemi-
arthroplasy following subcapital fracture of the femoral
neck. Cartilage and synovium specimens were washed
copiously in phosphate buffered saline (PBS) to remove
debris prior to processing for specific experiments. Insuffi-
cient cartilage was available to perform immunocyto-IMMUNOCYTOCHEMISTRY
Specimens of cartilage cut from specific regions of
femoral condyles (N=6, mean±SD age 73.6±6.2 years) or
from the superior pole of femoral heads (N=3, mean age
76.7±21.6 years) were frozen in Cryomatrix (Shandon) on
a chuck suspended in liquid nitrogen for 2–3 minutes.
Serial 8-m sections were cut and laid onto slides pre-
viously coated with Vectabond (Vector) to assist tissue
adherence. Cryostat sections of cartilage or synovium were
washed in Tris/HCl buffer, pH 7.4 (1 min 4°C) to remove
soluble receptors, then fixed in acetone (10 min, RT).
Sections were washed in PBS (5 min, RT) and blocked
(30 min, RT) with PBS containing 20% normal goat serum
then followed by a further wash in PBS (10 min, RT).
Sections were incubated with mouse monoclonal anti-
bodies to p55 and p75 TNF-R (kind gift of Dr M. Brockhaus,
Hoffman La Roche, Basel) or IgG1 isotype control (Becton
Dickinson). Unbound antibody was removed between this
and subsequent steps by washing in PBS (10 min, RT).
Antibody binding was detected by incubation (30 min, RT)
with goat-anti-mouse IgG1 linked to biotin and the signal
amplified by incubation (30 min, RT) with ExtraAvidin-
alkaline phosphatase conjugate (Sigma). Sections were
incubated for up to 15 min with Fast Red insoluble alkaline
phosphate substrate with levamisole (Sigma) and the re-
action stopped by flooding the slides with distilled water.
Comparison was made between sections stained with
specific monoclonal antibodies and sections from the same
tissue stained with isotype control. Cartilage samples
exhibiting chondrocyte TNF-R expression when examined
microscopically (×400) were scored as follows: + + +, over
10 positive cells/field; + +, 5–10 positive cell/field; +, up to
five positive cells/field. Photomicrographs of cartilage
were taken using Fujichrome 64 tungsten film which was
uprated one stop in the E6 (colour) process, to increase
contrast and colour saturation.Fig. 1. Diagram of the right knee joint showing the different
anatomical regions from which cartilage was obtained. Regions 1,
2 and 3 were located on the lateral femoral condyle, regions 4, 5
and 6 were located on the medial femoral condyle. Regions 1 and
4 were located at the anterior and regions 3 and 6 at the posterior
aspects of the knee joint.CULTURE OF CARTILAGE WITH TNF
Semicircular biopsies were cut in full depth cartilage
using a 3-mm biopsy punch and experiments performed as
described by Webb et al. (1997).7 Briefly, biopsies were
made from cartilage taken from each of six individual sites
on femoral condyles. Four or more replicate biopsies were
selected at random from each of the six biopsy pools
obtained from each knee; each biopsy was cut in two. One
half of each biopsy was cultured in RPMI 1640 containing
5% heat inactivated normal human AB serum alone (con-
trol), the other half of the biopsy pair was cultured in tissue
culture medium containing either 5, 1, 0.5, 0.25 or 0.1 ng
TNF. The cartilage degrading capacity of each of the five
different concentrations of TNF, was tested on biopsies
from specific regions of knee joints from four different
patients (N=20, mean age 67.8±9.2 years, range 50–86).
Biopsy replicates cultured with 5–0.25 ng TNF were incu-
bated (37°C, 5% CO2) for 14 days, those cultured with
0.1 ng TNF were incubated for 28 days, and the medium
changed every two days. Culture supernatants from each
time point were collected and stored at −20°C prior to
measurement of glycosaminoglycans (GAG) content bychemistry and tissue culture experiments on specimens
from the same donor. Cartilage from separate patient
groups was therefore used for each set of experiments.
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tants were adjusted for dry weight of biopsy and expressed
as g/mg cartilage. Results were expressed as percentage
increase in GAG release: % increase=([Test-Control]/
Control)×100.SYNOVIUM CULTURE
Specimens of synovium from NA (N=15, mean age
82.7±10.5, range 59–97 years) and OA subjects (N=37,
mean age 66.7±9.4, range 47–90 years) were chopped
finely and cultured for 24 hours essentially as described by
Webb et al. (1998).12 Supernatants were harvested, filtered
(40 m, Falcon), centrifuged (3500 rpm, 15 min) to remove
debris and stored in aliquots at −70°C.MEASUREMENT OF TNF IN SYNOVIUM SUPERNATANTS
TNF concentrations in serial dilutions of synovium
supernatants were measured by ELISA as described by
Westacott et al. (1997)13 with the following modification to
the detection step. After removal of the test supernatants
and diluted standards, wells were washed three times with
PBS containing 0.5% Tween (PBS/Tween). Polyclonal
sheep anti-human TNF (H91, NIBSC, Potters Bar, Herts)
was added to all wells and the plate incubated (1 h, RT).
Wells were further washed three time with PBS/Tween, and
rabbit anti-sheep-biotin (Chemicon, Harrow, Middx) added
before incubation for a further 1 hour at room temperature.
After further washing (×3) with PBS/Tween, streptavidin-
HRP (Amersham, Little Chalfont, Bucks) was added to all
wells and incubation continued (30 min, RT). Wells were
again washed three times prior to addition of peroxidase
substrate, tetramethylbenzide (Sigma, 60 mg/ml in sodium
acetate/citric acid buffer, pH 5.5), with further incubation for
30 minutes in the dark. The reaction was stopped by
addition of 10% H2SO4 and absorbance read at 450 nm. As
the dilution curve of supernatants was not linear when
compared with dilutions of standard TNF preparation, all
14results were subjected to PROBIT analysis.MEASUREMENT OF STNF-R IN SYNOVIUM SUPERNATANTS
The concentrations of both p55 and p75 sTNF-R were
measured in supernatants by ELISA. Non-crossreacting
antibodies, 5R13 for p55 sTNF-R and 7R10 for p75
sTNF-R, were kindly provided by Dr Sue Stephens (Cell-
tech Therapeutics, Slough, U.K.) and the assays performed
15as described by Armstrong et al. (1999).STATISTICAL ANALYSIS
The significance of the difference in GAG release from
cartilage biopsies cultured in the presence of TNF as
compared with biopsies cultured in medium alone was
assessed by Student’s t-test. The significance of the differ-
ence in the concentrations of TNF, p55 sTNF-R and p75
sTNF-R in NA as compared with OA synovium superna-
tants and between p55 and p75 sTNF-R measurements
within groups was assessed by t-test with Welch’s correc-
tion for non-equal variance on log-transformed values.
Correlations were sought between TNF and p55 or p75
sTNF-R measurements and between both sTNF-R
measurements within groups using Pearsons product
moment correlation.ResultsTable I
p55 TNF-R expression on chondrocytes in OA cartilage specimens obtained from six different regions on the
femoral condyles of six different knee joints
Patient Region 1 Region 2 Region 3 Region 4 Region 5 Region 6 Total
A ND + + − − ND ND 1/3
B ND + − − ND − 1/4
C + − − ND ND − 1/4
D + + + ND + ND − 3/5
E ND − − − ND − 0/4
F + + + − − − ND + 2/5
Total 3/3 3/6 0/5 1/5 0/0 1/5
(+) denotes degree of positivity, (−) denotes negative, ND (not done) denotes regions for which insufficient full
depth cartilage was available for processing.VISUALIZATION OF TNF-R IN CARTILAGE
To determine if TNF-R is expressed on chondrocytes
and whether the degree of expression varies in different
regions of the knee joint in vivo, freshly processed cartilage
was stained for both p55 and p75 TNF-R. In all, 24
specimens from six different knee joints were examined,
eight of which (33.3%) stained positive for p55 TNF-R
expression as shown in Table I. Differences in staining
were apparent in cartilage from different regions within the
same knee joint. For example, cartilage from patient A
showed positive staining for p55 TNF-R on chondrocytes in
region 2, whereas cartilage from regions 3 and 4 were
negative. Similarly, cartilage from patient D showed positive
staining for p55 TNF-R in regions 1, 2 and 4, whereas
cartilage from region 6 was negative. In addition, differ-
ences in staining were also apparent in the same regions in
different joints. For example, cartilage from patients C, D
and F, contained p55 TNF-R positive chondrocytes in
region 1, although only in cartilage from patient D were p55
TNF-R bearing chondrocytes detected in region 2. Typi-
cally, chondrocytes staining for p55 TNF-R were distributed
throughout the depth of the tissue; the majority of positive
staining chondrocytes were located in the superficial zone
(Fig. 2A). Chondrocytes staining for p55 TNF-R were
frequently seen in chondrones in cartilage near severe
osteoarthritic lesions (Fig. 2B). By comparison, Table II
shows only 3/24 (12.5%) sections from the same prepara-
tions stained positive for p75 TNF-R (Fig. 2C). Distribution
of p75 TNF-R-positive cells through the tissue was similar
to that of p55 TNF-R-positive cells, although the staining
was less intense. Interestingly, staining for the two receptor
216 C. I. Westacott et al.: TNF and focal loss of cartilage in OAtypes appeared to be mutually exclusive: those specimens
that were positive for p55 were negative for p75 TNF-R,
and vice versa. By contrast, none of the sections obtained
from NA femoral head cartilage stained positive for either
receptor type.Fig. 2. Visualization of TNF-R on chondrocytes in cartilage from femoral condyles of OA joints. (A) chondrocytes staining for p55 TNF-R near
the articulating region of OA cartilage (B) chondrocytes staining for p55 TNF-R in chondrones near severe osteoarthritic lesions (C)
chondrocytes staining for p75 TNF-R in OA cartilage.Table II
p75 TNF-R expression on chondrocytes in OA cartilage specimens obtained from six different regions on the
femoral condyles of six different knee joints
Patient Region 1 Region 2 Region 3 Region 4 Region 5 Region 6 Total
A ND − + + ND ND 2/3
B ND − − + ND − 1/4
C − − − ND ND − 0/4
D − − ND − ND − 0/4
E ND − − − ND − 0/4
F − − − − ND − 0/5
Total 0/3 0/6 1/5 2/5 0/0 0/5
(+) denotes degree of positivity, (−) denotes negative, ND (not done) denotes regions for which insufficient full
depth cartilage was available for processing.SUSCEPTIBILITY OF CARTILAGE TO LOW CONCENTRATIONS
OF TNF
To determine the effects on cartilage of TNF at the
concentrations likely to be produced by tissue within the
knee joint (0.1–5 ng), replicate biopsies of OA cartilage
from specific regions of the femoral condyles were incu-
bated in the presence of cytokine for a minimum of 14 days
and GAG release into supernatants measured. Differences
in cumulative GAG release from biopsies incubated in the
presence of TNF as compared with GAG released from
control biopsies incubated in medium alone were
assessed. The results for each of the four experiments
performed at each cytokine concentration are summarized
in Table III. Regions where TNF-induced GAG release into
the medium was significantly higher than controls wereconsidered to be susceptible to the effects of the cytokine
and termed positive (+), those where insignificant amounts
of GAG were released were termed negative (−). Variation
was observed within the same knee joint in susceptibility of
cartilage to the effects of 5 ng TNF. For example, cartilage
from regions 1, and 6 from patient 1 were susceptible to the
effects of 5 ng TNF whereas cartilage from regions 2 and
3 were not. Similarly, for patient 2, only cartilage from
regions 1, 3 and 5, but not regions 2 and 6, were suscep-
tible to the effects of 5 ng TNF. In addition, differences
were also seen at the same site in different knees. Although
cartilage from region 3 was tested with 5 ng TNF for all
four patients, only biopsies from patient 1 were susceptible
to the cytokine. Similarly, only in patient 4 was cartilage
from region 2 susceptible to the effects of 5 ng TNF.
Comparable variation in susceptibility of different regions
within the same knee and in the same region in different
knees were apparent in cartilage incubated in the presence
of 1, 0.5 and 0.25 ng TNF. Figure 3 shows a typical
experiment from each group illustrating the variation within
and between knees in susceptibility to the effects of
cytokine. Interestingly, the total number of regions respond-
ing to TNF decreased with cytokine concentration. For
Osteoarthritis and Cartilage Vol. 8 No. 3 217example, whilst 40% of all regions tested were susceptible
to the effects of 5 ng TNF, only 11% were susceptible to
0.25 ng TNF. None of the biopsies from any of the knees
were susceptible to the effects of 0.1 ng TNF, despite
extension of the incubation period to 28 days. When
divided into region of origin, more biopsies from the anterior
(1 and 4) and posterior (3 and 6) regions of the femoral
condyles were susceptible to the effects of TNF than
those from the central regions (2 and 5). Overall, there was
no significant difference in responsiveness in biopsies
originating from the lateral (10/45, 22%), as compared
to the remaining medial (8/37, 22%), regions of femoral
condyles.Table III
Summary of explant experiments on cartilage obtained from specific anatomical locations on the femoral condyles of 20 OA knee joints.
Biopsies, in replicates of four or more, were incubated for 14 or 28 days in the presence of 5, 1, 0.5, 0.25, 0.1 ng/ml TNF, and GAG release
into supernatants measured. Comparison was made between GAG release from biopsies incubated in the presence of TNF and that
released from biopsies incubated in medium alone
TNF
(ng/ml)
Patient Region 1 Region 2 Region 3 Region 4 Region 5 Region 6 Positive/Total*
5.0 1 + − − ND ND + 2/4
2 + − + ND + − 3/5
3 − − − + − − 1/6
4 − + − ND − + 2/5
8/20 (40%)
1.0 5 − − − − − − 0/6
6 + − − ND ND + 2/4
7 − + − + ND ND 2/4
8 ND − − − ND − 0/4
4/18 (22%)
0.5 9 + − − − − − 1/6
10 ND − + + − ND 2/4
11 − − − ND + − 1/5
12 ND − − ND − − 0/4
4/19 (21%)
0.25 13 − − − − ND − 0/5
14 + − + − ND − 2/5
15 ND − − − ND − 0/4
16 − − − ND ND − 0/4
2/18 (11%)
0.1 17 − − − − ND − 0/5
18 ND − − − ND − 0/4
19 − − − ND − ND 0/4
20 − − − − ND ND 0/4
0/17 (0%)
(+) denotes regions where TNF-induced GAG release was significantly greater (P<0.05) than corresponding control; (−) denotes regions
where TNF-induced GAG release was insignificant. *Denotes the number of regions responding to TNF/total number of regions examined.
ND (not done) denotes regions for which insufficient cartilage was available to make replicate biopsies.TNF AND STNF-R MEASUREMENTS IN SYNOVIUM SUPERNATANTS
Production of TNF by synovium may contribute to loss
of cartilage in knee joints in regions where high numbers of
p55 TNF-R are focused. However, TNF-R shed from the
surface of cells and solubilized in the joint space may bind
to TNF and effectively block bioavailability of the cytokine
at the target cell. To determine whether sufficient soluble
inhibitor can be produced to negate the effect of any TNF
present within the joint, TNF and both p55 and p75
sTNF-R were measured in supernatants from cultured
synovium. The concentrations of TNF measured in super-
natants from cultured NA and OA synovium are recorded
in Fig. 4. TNF measurements were significantly higher
(P=0.0004) in supernatants from OA synovium(752.1±1261.4 pg/ml, range 23–4575, N=37) than similar
supernatants from NA synovium (102.7±73.5 pg/ml, range
23–244, N=15). The concentrations of soluble p55 and p75
TNF-R measured in a subset of the same NA and OA
supernatants are recorded in Fig. 5. In supernatants from
NA synovium, measurements of p55 sTNF-R (1.38±1 ng/
ml, range 0.06–2.9, N=15) were significantly higher
(P=0.02) than those for p75 sTNF-R (0.4±0.18 ng/ml,
range 0.16–0.88, N=15). By contrast, measurements of
p55 sTNF-R in supernatants from OA synovium
(1.51±1.44 ng/ml, range 0.06–4.96, N=24) did not differ
significantly from those of p75 sTNF-R (0.89±0.43 ng/ml,
range 0.14–2.29, N=24). When measurements of p55
sTNF-R concentrations in supernatants from NA synovium
were compared with those from OA synovium, no signifi-
cant statistical difference between groups was apparent.
However, significantly more (P=0.0001) p75 sTNF-R was
detected in supernatants from OA synovium than similar
supernatants from NA synovium. To determine whether
synovium production of cytokine and soluble inhibitors was
concurrent, correlations were sought within groups
between measurements of TNF and those of p55 and p75
sTNF-R. In supernatants from NA synovium there was a
significant association between the concentrations of TNF
measured and p75 sTNF-R (r=0.77, P=0.0008, N=15),
although there was no significant association between the
cytokine and p55 sTNF-R (r= −0.18, P=0.51, N=15). In
supernatants from OA synovium, there was no significant
relationship between measurements of TNF and either
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GAG release from cartilage explants during 14 days culture in the
presence of (a) 5 ng/ml, (b) 1 ng/ml, (c) 0.5 ng/ml, (d) 0.25 ng/ml
TNF. Incubation of explants in the presence of (e) 0.1 ng/ml)
TNF was extended to 28 days. All values are the mean±SD of at
least 4 replicates. ND (not done) denotes regions where insuffi-
cient cartilage was available. Significant increase in GAG release
as compared with control is indicated by **P<0.01, *P<0.05
(paired t test). ND (not done) denotes regions for which insufficient
cartilage was available to make replicate biopsies.Fig. 4. TNF concentrations in supernatants from 24 hour cultures
of osteoarthritic (OA) and non-arthritic (NA) synovium.p55 (r=0.06, P=0.77, N=22) or p75 (r=0.25, P= −0.6,
N=22) sTNF-R. For example, the supernatant containing
the highest amount of cytokine (2492 pg/ml) contained low
amounts of both p55 sTNF-R and p75 sTNF-R (0.06 ng/ml
and 0.2 ng/ml respectively), whilst another supernatant
containing only 93 pg/ml TNF, contained relatively high
p55 and p75 sTNF-R measurements (3.19 ng/ml and
2.29 ng/ml respectively). On average, TNF measure-
ments were approximately seven-fold greater in super-
natants from OA synovium as compared with those from
NA synovium. By contrast, p75 sTNF-R measurements in
OA supernatants were only two-fold higher.
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from 24 hour cultures of osteoarthritic (OA) and non-arthritic (NA)
synovium.Discussion
In previous work we suggested a role for TNF in focal
loss of cartilage in osteoarthritis. Here we examine further
the criteria required for cytokine mediated cartilage dam-
age to occur at specific locations on femoral condyles.
Firstly, we determined whether the distribution of TNF-R
expression on chondrocytes in vivo paralleled those in
vitro. Here we show for the first time chondrocytes staining
for TNF-R in cartilage obtained from specific regions of OA
knee joints and flash-frozen less than 2 hours after surgery.
Moreover, more preparations stained for p55, the major
signal transducer of TNF-induced cellular responses, than
for p75 TNF-R. Previously we showed that cartilage from
different sites within the same joint varied in its response to
TNF, as measured by GAG release, and that such vari-
ation was directly linked to p55 TNF-R on chondrocytes
from the same region.7 The results reported here therefore
confirm the presence of such p55 TNF-R-bearing chondro-
cytes in fresh cartilage and further demonstrate that recep-
tor expression and, by inference, susceptibility to the
effects of TNF, is not consistent in all regions of the joint at
the same time.
For TNF-mediated cartilage damage to occur cytokine
produced within the joint, and contained in synovial fluid,
must have reasonable access to TNF-R-bearing chondro-
cytes. In normal human articular cartilage, chondrocytes in
the superficial zone express greater numbers of high affin-
ity binding sites for IL-1 and are therefore more sensitive to
stimulation by IL-1 than chondrocytes in deeper zones.16 If
chondrocytes in the superficial zone are also more respon-sive to TNF, then it could be argued that in the OA
cartilage used in these experiments, the zone containing
most TNF-sensitive chondrocytes has been lost. This
suggestion is not borne out by the results. Whilst chondro-
cytes staining for p55 TNF-R were detected throughout
the cartilage matrix, intensely staining chondrocytes were
usually detected nearest the articulating surface of carti-
lage, whether it was fibrillated or not, as well as in chon-
drones in cartilage from regions with severe lesions. These
observations are similar to those of Kammerman et al.
(1996)17 where chondrocytes staining intensely for p55
TNF-R were detected in fibrillated canine cartilage from
which proteoglycan had been lost. Thus in human joints,
the spatial location of p55 TNF-R bearing chondrocytes
within matrix and differential expression within joints is
likely to predispose cartilage from specific regions to
cytokine-induced damage.
For TNF to be associated with focal loss of cartilage
in vivo, chondrocytes must be responsive to the amount of
cytokine produced locally. Earlier work showed site-related
differences in susceptibility to the effects of 10 ng/ml TNF
in explants from both OA and NA cartilage.7 However, the
amount of cytokine used was higher than that measured in
OA synovial fluids (0.02–1.2 ng/ml)3 or supernatants from
cultured OA synovium (0.02–5.0 ng/ml) and certainly out-
side the range likely to be found in NA joints.4 We next
performed similar experiments using explants of OA carti-
lage from specific regions of different joints together with
much less cytokine. Here we show GAG release to be
significantly increased in supernatants from susceptible
explants cultured in the presence of 5 ng, 1 ng, 0.5 ng or
0.25 ng TNF. Variation in susceptibility was observed at
different sites within the same knee joint which were similar
to that observed with 10 ng TNF.7 In addition, differences
in susceptibility were also seen at the same site in different
knees. Overall there was no apparent difference in respon-
siveness to TNF in biopsies originating from the lateral
as compared to the medial femoral condyles or in macro-
scopically normal cartilage as compared with damaged
cartilage. These observations suggest that by end-stage
disease, as judged by the need for surgery, macro-
scopically normal OA cartilage also becomes susceptible to
the effects of cytokines. Although less GAG was released
from the explants in these experiments, the results are
consistent with our earlier findings and demonstrate for the
first time that TNF at concentrations likely to be found in
OA, and some NA, joints can indeed degrade cartilage.
Interestingly, the number of specimens responding to TNF
decreased with concentration until none of the explants
responded to 0.1 ng/ml cytokine.
It is now well documented that receptors for many
cytokine species are shed from the surface of various cell
types and act as soluble inhibitors by reducing availability
of the cytokine. The extracellular portion of both p55 and
p75 TNF-R are released by proteolytic cleavage at the
membrane level and the resulting sTNF-R have been
detected in the serum of normal individuals,18 as well as in
biological fluids from patients with a variety of clinical
conditions.10,19,20,15 It thus became important to determine
whether in OA the balance between agonist and antagonist
are such that the net effect of TNF at the target cell is
abrogated or significantly reduced. Since no detectable p55
or p75 sTNF-R were found in supernatants from cultured
OA chondrocytes9 it was considered unlikely that chondro-
cytes contribute significantly to synovial fluid sTNF-R con-
centrations. We therefore measured concurrently the
concentrations of both sTNF-Rs and TNF in OA and NA
220 C. I. Westacott et al.: TNF and focal loss of cartilage in OAsynovium supernatants. In agreement with previous
studies,4 TNF concentrations were significantly higher in
supernatants from cultured OA synovium as compared with
NA synovium. For sTNF-R, measurements of p55 were
higher in OA supernatants, but not statistically so, whereas
concentrations of p75 were significantly higher in OA as
compared with NA supernatants. As incubation of synovial
fibroblasts with exogenous TNF results in shedding of p75
TNF-R from the cell surface,21 correlations between the
two parameters were expected. In NA supernatants there
was indeed a significant relationship between p75 TNF-R
and TNF measurements which supported our prediction.
As TNF induces a time and dose dependent increase in
the release of p75, but not p55 TNF-R, from the surface of
monocytes in vivo,22 our observations indicate the exist-
ence of a similar mechanism in NA synovial cells. By
contrast, in OA supernatants, no significant association
was found between measurements of the two molecules.
Similarly, no correlation was found between measurements
of TNF and either sTNF-R in synovial fluids from patients
with OA.10 Previous work in vivo20 and in vitro23 showed
that sTNF-R release occurs some hours after exposure to
TNF. Perhaps in a chronic condition such as OA, cells in
the synovium may be exposed to relatively high con-
centrations of TNF over a long period so that the mech-
anism by which binding of cytokine to its receptor results
in shedding of sTNF-R becomes dysphasic or even
attenuated with time.
Attempts to quantify the inhibitory capacity of sTNF-R
using in-vitro experiments20 suggest that 5 ng/ml p55
sTNF-R is required to reduce the bioactivity of 585 pg/ml
TNF by 66%, whereas 95% reduction of the same amount
of cytokine was achieved only by 500 ng/ml p55 sTNF-R.
By comparison, the same amount of p75 sTNF-R was
inadequate to block the response. The data reported here
show only one of 13 supernatants from OA synovium
contained p55 sTNF-R in the region of 5 ng/ml, whereas
none of the supernatants contained greater than 2.3 ng/ml
p75 sTNF-R. In OA joints it therefore seems unlikely that
inhibitory activity in the form of shed receptors is sufficient
to bring about significant diminution of TNF-mediated
activities. Moreover, neither p55 sTNF-R nor p75 sTNF-R
were found in supernatants from cultured OA chondro-
cytes9 although TNF was detected by immunocyto-
chemistry in OA but not NA chondrocytes.24 Consequently,
the balance between TNF and its soluble inhibitors is
likely to be even more biased toward agonistic activity in
the immediate extracellular environment of OA chondro-
cytes than in the joint fluid. In addition, cytokine:inhibitor
complexes may serve as slow release reservoirs for bio-
active TNF effectively prolonging the circulation of
cytokine within the joint.
Taken together, the results presented here provide
further support for TNF contributing to the process(es)
leading to focal loss of cartilage in OA. It remains to be
determined, however, just how TNF-R become up-
regulated on chondrocytes in cartilage from specific
regions. The answer may lie in the differences in weight-
bearing experienced by chondrocytes in cartilage from
different regions of the joint. Loading has a profound effect
on chondrocyte metabolism;25 shear stress can alter IL-6
mRNA expression26 and IL-1 and TNF production is
altered by mechanical stress.27 If environmental changes
of the type evoked by loading alter chondrocyte expression
of TNF-R, then an explanation for focal loss of cartilage in
OA would be identified.References
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